Skip to content
Screener

Baxter International BAX Healthcare Systems & Technologies — Net Sales

Other segment segments

Medical Products & Therapies
$1.29B+1.8%
Pharmaceuticals
$621M+6.9%

Similar metrics at other companies

DuPont de Nemours, Inc. logo
DDHealthcare Technologies — Net Sales
$467M+11.5%
DuPont de Nemours, Inc. logo
DDHealthcare & Water Technologies — Net Sales
$806M+5.6%
DENTSPLY SIRONA logo
XRAYWellspect Healthcare — Net Sales
$86M+7.5%
Brady Corporation logo
BRCHealthcare Identification — Net Sales
$35.15M-0.8%
SOL
SOLSHealthcare Packaging — Net Sales
$47M+9.3%
Honeywell International logo
HONAerospace Technologies — Net Sales
$4.53B+5.2%

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$14.66B+22.3%
Enterprise value$12.86B+22.1%
P/S1.3×+0.2×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%—
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0×0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Baxter International’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:50 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028962
(in millions)Three Months Ended March 31, 2026 / U.S.Three Months Ended March 31, 2026 / InternationalThree Months Ended March 31, 2026 / TotalThree Months Ended March 31, 2025 / U.S.Three Months Ended March 31, 2025 / InternationalThree Months Ended March 31, 2025 / Total
Medical Products & Therapies6915941,2857295331,262
Care & Connectivity Solutions315120435316111427
Front Line Care1987227020275277
Healthcare Systems & Technologies513192705518186704
Injectables & Anesthesia180121301195140335
Drug Compounding—320320—246246
Pharmaceuticals180441621195386581
Other513990483078

Item 1. Financial Statements (unaudited)

FAQ

What is Baxter International's healthcare systems & technologies — net sales?
Baxter International (BAX) reported healthcare systems & technologies — net sales of $705M in Q1 2026.
How has Baxter International's healthcare systems & technologies — net sales changed year-over-year?
Baxter International's healthcare systems & technologies — net sales increased by 0.1% year-over-year, from $704M to $705M.
What is the long-term trend for Baxter International's healthcare systems & technologies — net sales?
Over 3 years (2021 to 2025), Baxter International's healthcare systems & technologies — net sales has grown at a 143.8% compound annual growth rate (CAGR), from $212M to $3.07B.
What does healthcare systems & technologies — net sales mean?
The total revenue generated from the sale of medical instruments, hospital beds, and digital health solutions within the segment, net of returns, allowances, and discounts. This is the primary indicator of market demand and commercial success for the segment's product portfolio.

Ask your AI about Baxter International's healthcare systems & technologies — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude